Windward Bio: OrbiMed holds 3.56M Series A shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Windward Bio Group AG (WWB) Form 3 lists OrbiMed Private Investments IX, LP as record holder of 3,561,936 Series A preferred shares, 1,611,008 Series B preferred shares, 216,668 warrants and 531,632 common shares as of November 12, 2026. The preferred shares convert on a 1-to-1 basis into common shares immediately before the initial public offering closes; the warrants are exercisable at $0.02 and expire May 12, 2036. OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC may be deemed to have voting and investment power, but disclaim beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series A Preferred Shares F3, F1, F2 | -- | -- | -- |
| Holding | Series B Preferred Shares F3, F1, F2 | -- | -- | -- |
| Holding | Warrants (right to buy) F5, F4, F1, F2 | -- | -- | -- |
| Holding | Common Shares F1, F2 | -- | -- | -- |
Footnotes (5)
- F1. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
- F2. This report on Form 3 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F3. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
- F4. The warrants are fully vested and exercisable.
- F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
Key Figures
Key Terms
initial public offering financial
voting and investment power regulatory
pecuniary interest regulatory
fully vested and exercisable financial
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of the WWB warrants reported by OrbiMed?
AI-generated analysis. How Rhea-AI works. Not financial advice.